Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Patients in Europe Wait an Average 531 Days to Get New Medicines, Says Report

  • Post author:PacConAdmin
  • Post published:June 13, 2024
  • Post category:Uncategorized

Due to a combination of confounding factors in the regulatory system and the market, patients in Europe wait an average of 531 days to access new medicines, according to three…

Continue ReadingPatients in Europe Wait an Average 531 Days to Get New Medicines, Says Report

Supreme Court Rejects Challenge to Mifepristone

  • Post author:PacConAdmin
  • Post published:June 13, 2024
  • Post category:Uncategorized

The US Supreme Court tossed out a challenge to the FDA’s approval of the use of the abortion drug mifepristone (Mifeprex), ruling that the plaintiffs did not have standing to…

Continue ReadingSupreme Court Rejects Challenge to Mifepristone

FDA Research Strives to Understand the Ever-Evolving World of AI-Powered Devices

  • Post author:PacConAdmin
  • Post published:June 12, 2024
  • Post category:Uncategorized

The FDA has established an Artificial Intelligence Program with a focus on six research topics that delve into the far-reaching implications of medical devices powered by AI and machine learning.…

Continue ReadingFDA Research Strives to Understand the Ever-Evolving World of AI-Powered Devices

House’s Proposed Budget Offers FDA No New Funding

  • Post author:PacConAdmin
  • Post published:June 12, 2024
  • Post category:Uncategorized

The House’s fiscal 2025 Agriculture-FDA bill, released Monday, keeps spending almost flat, providing the FDA with $6.75 billion in total funding, short of the agency’s $7.2 billion budget request. Source:…

Continue ReadingHouse’s Proposed Budget Offers FDA No New Funding

Abbott HeartMate Sees 4th Class I Recall; Medline Sees Recall for Endotracheal Tube

  • Post author:PacConAdmin
  • Post published:June 12, 2024
  • Post category:Uncategorized

The FDA has deemed two recalls as Class I — Medline Industries for issues with its Sub-G Endotracheal Tube and Abbott for yet another issue with its HeartMate 3 Left…

Continue ReadingAbbott HeartMate Sees 4th Class I Recall; Medline Sees Recall for Endotracheal Tube

Alzheimer’s Trials Guidance Feedback Calls for Clarity on Disease Later-Stage Protocols

  • Post author:PacConAdmin
  • Post published:June 12, 2024
  • Post category:Uncategorized

Alzheimer’s drugmakers including Biogen, Eli Lilly and Eisai, as well as consumer advocacy group Public Citizen, have characterized a recent FDA guidance on developing drugs for Alzheimer’s as lacking in…

Continue ReadingAlzheimer’s Trials Guidance Feedback Calls for Clarity on Disease Later-Stage Protocols

AdvaMed Wins Appeal in Right to Repair Over Library of Congress

  • Post author:PacConAdmin
  • Post published:June 11, 2024
  • Post category:Uncategorized

AdvaMed notched a victory last Friday when the US Court of Appeals ruled in its favor in the latest saga over what the association describes as preventing “unauthorized and unregulated…

Continue ReadingAdvaMed Wins Appeal in Right to Repair Over Library of Congress

Teva Must Remove ProAir HFA Device Patents From Orange Book, Judge Orders

  • Post author:PacConAdmin
  • Post published:June 11, 2024
  • Post category:Uncategorized

A New Jersey federal judge has ordered Teva Pharmaceuticals to remove from the Orange Book five patents on its ProAir HFA asthma inhalation device, clearing the way for Amneal Pharmaceuticals…

Continue ReadingTeva Must Remove ProAir HFA Device Patents From Orange Book, Judge Orders

AdComm Unanimously Supports Lilly’s Antiamyloid Antibody for Alzheimer’s

  • Post author:PacConAdmin
  • Post published:June 11, 2024
  • Post category:Uncategorized

The FDA’s 11-person Peripheral and Central Nervous System Drugs Advisory Committee unanimously endorsed both the efficacy and safety of Lilly’s antiamyloid antibody donanemab, saying that people with Alzheimer’s disease and…

Continue ReadingAdComm Unanimously Supports Lilly’s Antiamyloid Antibody for Alzheimer’s

Human Umbilical Cord Product Lacks IND, BLA, Company Slapped With Untitled Letter

  • Post author:PacConAdmin
  • Post published:June 11, 2024
  • Post category:Uncategorized

The FDA sent an untitled letter to Achieve Vitality, which markets a product claiming to offer regenerative therapy, for offering an injectable product derived from human umbilical cord for which…

Continue ReadingHuman Umbilical Cord Product Lacks IND, BLA, Company Slapped With Untitled Letter
  • Go to the previous page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 144
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company